New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 18, 2014
05:52 EDTSAGESage Therapeutics 5M share IPO priced at $18.00
The deal priced at the high end of the revised $17.00-$18.00 range. JPMorgan and Goldman acted as joint book running managers for the offering.
News For SAGE From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 22, 2015
12:01 EDTSAGELigand earns milestone payment from Sage Therapeutics for SAGE-547
Ligand (LGND) announced that it has earned a $500,000 milestone payment from SAGE Therapeutics (SAGE) relating to the treatment of the first patient in SAGE’s Phase 3 open-label expanded access protocol, designated Study 302. Study 302 is designed to offer SAGE-547 to patients affected by super-refractory status epilepticus and to evaluate the safety of SAGE-547 in patients with SRSE. SAGE has reported that the results from this clinical trial, along with results from SAGE's planned Phase 3 placebo-controlled clinical trial - called the STATUS Trial – and other clinical data obtained from the SAGE-547 development program are intended to form the basis of a New Drug Application submission.
April 20, 2015
08:47 EDTSAGESage Therapeutics announces first patient treated under SAGE-547 Phase 3 trial
Subscribe for More Information
07:18 EDTSAGEAmerican Academy of Neurology to hold annual meeting
Subscribe for More Information
April 15, 2015
06:20 EDTSAGESage Therapeutics 2.29M share Secondary priced at $52.50
Subscribe for More Information
April 13, 2015
16:37 EDTSAGESage Therapeutics files to sell $100M of common stock
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use